Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 60

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 60
---
 effective as of the time of consummation of the change in control.

2019 Employee Stock Purchase Plan

Our 2019 Employee Stock Purchase Plan (the “ESPP”) was approved by our board of directors in April 2019 and our shareholders in June 2019. In the event of a change in control, an acquiring or successor corporation may assume our rights and obligations under outstanding purchase rights or substitute substantially equivalent purchase rights. If the acquiring or successor corporation does not assume or substitute for outstanding purchase rights, then the purchase date of the offering periods then in progress will be accelerated to a date prior to the change in control.

Our ESPP has not yet been made available to employees. Our compensation and human capital committee has the authority to amend, suspend or terminate our ESPP at any time.**

<div align='center'>47</div>

Equity Compensation Plan Information The following table sets forth equity compensation plan information as of December 31, 2024:

| Plan Category                                              |     | Outstanding  
 Options,     
 Warrants and 
 Rights(1)    
 (#)          |            |     | Weighted- 
 Average   
 Exercise  
 Price(2)  
 ($)       |       |     | Available   
 for Future  
 Issuance(3) 
 (#)         |            |
| Equity compensation plans approved by security holders(4)  |     |              | 26,301,263 |     |           | 15.11 |     |             | 23,704,482 |
| Equity compensation plans not approved by security holders |     |              |          — |     |           |     — |     |             |          — |
| Total                                                      |     |              | 26,301,263 |     |           | 15.11 |     |             | 23,704,482 |

| (1) | Reflects the number of securities to be issued upon the exercise of outstanding options and rights to receive shares pursuant to RSU and PSU awards. Includes 12,295,297 outstanding options, 10,174,852 outstanding, unvested RSUs and 3,831,114 outstanding, unvested maximum number of PSUs eligible to be earned. |

| (2) | Represents the outstanding options’ weighted-average exercise price and does not take into account the shares issuable upon vesting of outstanding RSUs and PSUs, which do not have an exercise price. |

| (3) | Represents the number of securities remaining available for future issuance under